• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Public Health . Comparative evaluation of SARS-CoV-2 laboratory testing data sources for U.S. COVID-19 public health surveillance, 2020-2024

tetano

Editor, Senior Moderator
Front Public Health


. 2026 Jun 23:14:1827546.
doi: 10.3389/fpubh.2026.1827546. eCollection 2026.
Comparative evaluation of SARS-CoV-2 laboratory testing data sources for U.S. COVID-19 public health surveillance, 2020-2024

Alisha Kalangara[SUP] 1 2 [/SUP], Conor Millard[SUP] 1 2 [/SUP], Amber K Winn[SUP] 2 [/SUP], Tricia A Aden[SUP] 3 [/SUP], Kim Del Guercio[SUP] 4 3 [/SUP], Jourdan DeVies[SUP] 5 [/SUP], Stephanie Dietz[SUP] 5 [/SUP], Andrew Godoshian[SUP] 6 [/SUP], Jason Hall[SUP] 4 3 [/SUP], Teresa Jue[SUP] 3 [/SUP], Joseph Miller[SUP] 7 [/SUP], Erica Billig Rose[SUP] 2 [/SUP], Zachary R Smith[SUP] 6 [/SUP], Benjamin J Silk[SUP] 2 [/SUP]


Affiliations
Abstract

Introduction: SARS-CoV-2 laboratory testing data were collected by the U.S. Centers for Disease Control and Prevention for surveillance during the COVID-19 pandemic response. Understanding how these existing data correlate and diverge can help guide their use and interpretation.
Method: We evaluated COVID-19 Electronic Laboratory Reporting (CELR), the National Respiratory and Enteric Virus Surveillance System (NREVSS), Increasing Community Access to Testing, Treatment and Response (ICATT) program, and commercial laboratory data from 2020 to 2024. SARS-CoV-2 testing volume, viral activity, and viral activity trends were calculated for each source during periods marked by key events. Key events included Delta and Omicron variant emergence, at-home testing availability, and public health emergency conclusion. Viral activity was characterized by percent positivity, the median percent of tests positive for SARS-CoV-2. Viral activity trends were measured using Spearman's correlation coefficients of normalized percent positivity between NREVSS and each of the data sources, along with match rates between the two sources from weekly trajectory categorization (increasing, stable, decreasing) comparisons.
Results: SARS-CoV-2 testing volume decreased across time, most notably since January 2022. Viral activity measures showed that CELR (8.4%) and NREVSS (7.7%) had lower median weekly percent positivity compared to ICATT (18.5%) and commercial laboratories (11.0%). Viral activity trends between NREVSS and CELR (ρ = 0.93) and NREVSS and commercial laboratory (ρ = 0.85) were highly correlated, and less correlated between NREVSS and ICATT (ρ = 0.58). Week-to-week trajectory match rates indicated concordant viral trends across data sources with 89% for CELR, 79% for commercial laboratories, and 67% for ICATT when compared to NREVSS.
Discussion: ICATT and commercial laboratory data sources consistently reported higher activity levels than CELR and NREVSS, suggesting differences in testing and care-seeking among the underlying populations represented, and the effects of varying reporting practices over time. However, trend correlations with NREVSS were high and few differences were observed in week-to-week trajectories. While these findings may be in part due to overlap in data sources, they also suggest that viral activity trends were relatively consistent across sources. A broad set of laboratory-based surveillance data sources effectively captured trends in SARS-CoV-2 circulation despite the evolving nature of testing and reporting during and after the COVID-19 pandemic.

Keywords: COVID-19 electronic laboratory reporting; COVID-19 response; National Respiratory and Enteric Virus Surveillance System; SARS-CoV-2; commercial laboratory; increasing community access to testing; surveillance.

 
Back
Top